ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 114 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2024. The put-call ratio across all filers is 0.27 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $207,916 | -63.0% | 34,543 | -31.4% | 0.00% | – |
| Q1 2024 | $561,303 | -71.9% | 50,341 | -62.5% | 0.00% | -100.0% |
| Q4 2023 | $1,999,331 | +209.0% | 134,222 | -0.4% | 0.00% | – |
| Q3 2023 | $647,038 | -3.5% | 134,739 | +50.8% | 0.00% | – |
| Q2 2023 | $670,835 | +60.6% | 89,372 | -3.3% | 0.00% | – |
| Q1 2023 | $417,748 | +46680.3% | 92,412 | +16.6% | 0.00% | – |
| Q4 2022 | $893 | -99.9% | 79,277 | +19.3% | 0.00% | – |
| Q3 2022 | $636,000 | – | 66,473 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $58,490,548 | 25.26% |
| Vivo Capital, LLC | 4,220,048 | $25,446,889 | 2.35% |
| MPM BioImpact LLC | 2,180,864 | $13,150,610 | 2.04% |
| Vestal Point Capital, LP | 3,600,000 | $21,708,000 | 1.62% |
| Redmile Group, LLC | 4,036,451 | $24,339,800 | 1.47% |
| Privium Fund Management B.V. | 396,966 | $2,270,646 | 0.58% |
| Paradigm Biocapital Advisors LP | 1,575,605 | $9,500,898 | 0.36% |
| Nan Fung Group Holdings Ltd | 41,950 | $252,959 | 0.27% |
| Orbimed Advisors | 1,894,462 | $11,423,606 | 0.23% |
| Affinity Asset Advisors, LLC | 100,000 | $603,000 | 0.07% |